PACB Pacific Biosciences of California, Inc. - Common Stock
NASDAQ · Life Sciences Tools & Services · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 6, 2026
$2,54
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$1,0752-Wochen-Tief
$2,7352-Wochen-Hoch
Marktkapitalisierung (MRQ)
$789M
P/E (TTM)
-6.2
EPS (TTM)
$-0.41
Umsatz (TTM)
$159M
Ihre Abzeichen
52W-Spanne
$1–$3
Analystenbewertung
BUY
Kursziel
$2
P/E
-6.2
ROE
-929.3%
Nettogewinnmarge
-82.5%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
PACB Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$2.54
Marktkapitalisierung (MRQ)
$789M
P/E (TTM)
-6.2
EPS (TTM)
$-0.41
Umsatz (TTM)
$159M
ROE (TTM)
-929.3%
52W-Spanne
$1–$3
PACB Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Über Pacific Biosciences of California, Inc. - Common Stock Unternehmensübersicht von Wikipedia
Pacific Biosciences of California, Inc. (a.k.a. PacBio) is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.
History
The company was founded based on research done at Cornell University that combined semiconductor processing and photonics with biotechnology research. Three graduate students in the lab of Professors Watt W. Webb — Jonas Korlach — and Harold Craighead — Steve Turner and Mathieu Foquet — became the first employees.
It began under the name Nanofluidics, Inc. The company raised nearly US$400,000,000 in six rounds of primarily venture capital financing, making it one of the most capitalized startups in 2010 leading up to their public offering in October of that year. Key investors included Mohr Davidow Ventures, Kleiner, Perkins, Caufield & Byers, Alloy Ventures, and Wellcome Trust.
The company's first commercial product, the PacBio RS, was sold to a limited set of customers in 2010 and was commercially released in early 2011. A subsequent version of the sequencer called the PacBio RS II was released in April 2013.
Leadership
In 2004, Kleiner Perkins entrepreneur-in-residence Hugh Martin became CEO. On 6 January 2012 board member Michael Hunkapiller, PhD assumed the role of CEO. Hunkapiller retired in September 2020, and was replaced by chairman of the board Christian Henry. Henry was a former executive VP and chief commercial officer of Illumina before joining the board at PacBio in July 2018.
Illumina: attempted acquisition
On 1 November 2018, Illumina, Inc. agreed to purchase PacBio for US$1.2 billion in cash. The deal was expected to close in the fourth quarter of 2019. In December 2019, the Federal Trade Commission sued to block the acquisition. The deal was abandoned with an announcement on 2 January 2020. Illumina further agreed to pay Pacific Biosciences a $98 million US termination fee plus previously agreed upon deal extension payments of $22 million US in February and $6 million US in March 2020.
Sequencing technology
Sequencing instruments
The company's first scientific instrument, called the PacBio RS, was released to a limited set of customers in late 2010., with full commercial release in early 2011. Sequencing provider GATC Biotech was selected by Pacific Biosciences as its first European service provider in late 2010. A new version of the sequencer was released in April 2013 it produced longer sequence reads and higher throughput than the original RS instrument. The RS instrument will officially be supported until the end of 2021. In September 2015, the company released a new sequencing instrument, the Sequel System, with increased sequencing capacity at a smaller size and lower price compared to the PacBio RS II. Subsequently, in October 2022, PacBio launched a new sequencing system, which can sequence 1,300 human genomes per year as compared to 86 per year of the previous PacBio sequencing machines.
Reagents and SMRT Cells
To use either instrument, customers must also purchase reagent packs for DNA preparation and sequencing and small consumables called "SMRT Cells." Cells for early forms of the sequencer are slightly less than one-centimeter square and contains tens of thousands of zero-mode waveguides, whereas newer systems have a higher density of cells and contain 25 million zero-mode waveguides (ZMWGs), allowing for faster DNA sequencing.
Software and applications
Their secondary analysis bioinformatics product for the RS, called “SMRT Analysis”, was open source. For the Sequel system the secondary analysis software was reorganized as the "SMRT Link" application. In 2013, the company released new bioinformatics tools for automated genome assembly (HGAP) and finishing (Quiver).
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
SektorHealthcare
BrancheLife Sciences Tools & Services
Mitarbeiter485
LandUS
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$160M2016-12-31 → 2025-12-31
EPS$-1.822018-12-31 → 2025-12-31
Freier Cashflow$-114M2016-12-31 → 2025-12-31
Nettogewinnmarge-82.5%2016-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | PACB | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | -6.25-Jahres-Durchschnitt ≈-7.8 | ≈-7.8 | · | · | |
| P/S (TTM) | 5.05-Jahres-Durchschnitt ≈13.8 | ≈13.8 | 4.6 | Unterbewertet | |
| K/B (MRQ) | -23.85-Jahres-Durchschnitt ≈23.9 | ≈23.9 | · | · | |
| Kurs / FCF (TTM) | -6.45-Jahres-Durchschnitt ≈-12.5 | ≈-12.5 | · | · | |
| Kurs / Cashflow (TTM) | -6.75-Jahres-Durchschnitt ≈-13.1 | ≈-13.1 | · | · | |
| Kurs / Materieller Buchwert (MRQ) | -17.1 | · | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | PACB | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Bruttogewinnmarge (TTM) | 36.4%5-Jahres-Durchschnitt ≈32.5% | ≈32.5% | 46.6% | Schwach | |
| Betriebsgewinnmarge (TTM) | -83.5%5-Jahres-Durchschnitt ≈-244.3% | ≈-244.3% | -22.1% | Schwach | |
| EBITDA Margin (EBITDA-Marge) | -346.1%5-Jahres-Durchschnitt ≈-244.3% | ≈-244.3% | -22.1% | Schwach | |
| Vorgewinnmarge (TTM) | -82.0%5-Jahres-Durchschnitt ≈-231.3% | ≈-231.3% | -15.3% | Schwach | |
| Nettogewinnmarge (TTM) | -82.5%5-Jahres-Durchschnitt ≈-215.9% | ≈-215.9% | -21.1% | Schwach | |
| ROA (TTM) | -16.7%5-Jahres-Durchschnitt ≈-24.6% | ≈-24.6% | -8.3% | Schwach | |
| ROE (TTM) | -929.3%5-Jahres-Durchschnitt ≈-363.3% | ≈-363.3% | -10.9% | Schwach | |
| ROIC | -10360.5%5-Jahres-Durchschnitt ≈-2629.4% | ≈-2629.4% | -16.2% | Schwach |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | PACB | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 4.95-Jahres-Durchschnitt ≈7.8 | ≈7.8 | 4.5 | Starke Liquidität | |
| Quick Ratio (MRQ) | 3.95-Jahres-Durchschnitt ≈7.1 | ≈7.1 | 1.7 | Starke Liquidität |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | PACB | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 3.9%5-Jahres-Durchschnitt ≈20.1% | ≈20.1% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 7.6%5-Jahres-Durchschnitt ≈16.6% | ≈16.6% | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | 15.2% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | PACB | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.25-Jahres-Durchschnitt ≈0.1 | ≈0.1 | 0.3 | Schwach | |
| Inventory Turnover (Lagerumschlag) | 2.15-Jahres-Durchschnitt ≈2.5 | ≈2.5 | 3.5 | Schwach | |
| Receivables Turnover (Forderungsumschlag) | 5.15-Jahres-Durchschnitt ≈5.9 | ≈5.9 | 5.8 | Schwach | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$329.9K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-97.7%
Nächster Bericht
Nov 03, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 3, 2026 | $-0.14 | $-0.13 | -7.9% |
| 31. März 2026 | $-0.12 | $-0.14 | 12.7% | |
| 31. Dezember 2025 | $-0.12 | $-0.15 | 20.3% | |
| 30. September 2025 | $-0.13 | $-0.15 | 16.1% | |
| 30. Juni 2025 | $-0.14 | $-0.17 | 19.3% | |
| 31. März 2025 | $-1.44 | $-0.19 | -646.9% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $160M | $154M | $201M | $128M | $131M | $79M | $91M | $79M | $93M | $91M | $93M | $61M | |
| Cost of Revenue | $114M | $117M | $148M | $79M | $72M | $46M | $56M | $54M | $59M | $47M | $39M | $37M | |
| Gross Profit | $46M | $37M | $53M | $49M | $59M | $33M | $35M | $25M | $35M | $44M | $53M | $23M | |
| R&D Expense | $97M | $135M | $187M | $193M | $113M | $64M | $60M | $63M | $65M | $68M | $60M | $48M | |
| SG&A Expense | $141M | $175M | $170M | $161M | $124M | $73M | $75M | $63M | $59M | $48M | $45M | $38M | |
| Operating Expenses | $600M | $512M | $387M | $356M | $269M | $137M | $135M | $126M | $124M | $115M | $83M | $86M | |
| Operating Income | $-554M | $-474M | $-334M | $-307M | $-210M | $-104M | $-101M | $-101M | $-90M | $-71M | $-29M | $-63M | |
| Interest Expense | · | · | $14M | $15M | $13M | $267.0K | $3M | $2M | $3M | $3M | $3M | $3M | |
| Other Non-op | $15M | $24M | $33M | $8M | $93.0K | $2M | $1M | $848.0K | $516.0K | $103.0K | $364.0K | $-478.0K | |
| Pretax Income | $-546M | $-310M | $-318M | $-314M | $-275M | $29M | $-84M | · | · | · | · | · | |
| Income Tax | $318.0K | $316.0K | $-11M | $0 | $-94M | · | · | · | · | · | · | · | |
| Net Income | $-546M | $-310M | $-307M | $-314M | $-181M | $29M | $-84M | $-103M | $-92M | $-74M | $-32M | $-66M | |
| EPS (Basic) | $-1.82 | $-1.13 | $-1.21 | $-1.40 | $-0.89 | $0.18 | $-0.55 | $-0.76 | · | · | · | · | |
| EPS (Diluted) | $-1.82 | $-1.59 | $-1.21 | $-1.40 | $-0.89 | $0.17 | $-0.55 | $-0.76 | · | · | · | · | |
| Shares (Basic) | 299,959,000 | 274,488,000 | 253,629,000 | 224,550,000 | 204,136,000 | 165,187,000 | 152,527,000 | 135,094,000 | · | · | · | · | |
| Shares (Diluted) | 299,959,000 | 288,366,000 | 253,629,000 | 224,550,000 | 204,136,000 | 174,970,000 | 152,527,000 | 135,094,000 | · | · | · | · | |
| EBITDA | $-554M | $-474M | $-334M | $-307M | $-210M | $-104M | $-101M | $-94M | $-81M | $-67M | $-25M | $-59M |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $64M | $55M | $180M | $325M | $461M | $82M | $30M | $19M | $17M | $17M | $34M | $36M | |
| Short-term Investments | $216M | $335M | $452M | $447M | $584M | $237M | $19M | $84M | $46M | $55M | $49M | $65M | |
| Receivables | $35M | $28M | $37M | $19M | $24M | $17M | $15M | $9M | $13M | $11M | $5M | $3M | |
| Inventory | $49M | $59M | $57M | $50M | $25M | $14M | $13M | $18M | $23M | $16M | $11M | $11M | |
| Prepaid Expense | $11M | $19M | $17M | $10M | $7M | $5M | $3M | $3M | $2M | $10M | $12M | $2M | |
| Other Current Assets | · | · | · | · | · | · | · | · | $931.0K | $476.0K | $741.0K | $107.0K | |
| Current Assets | $375M | $496M | $742M | $852M | $1.10B | $356M | $81M | $132M | $102M | $109M | $111M | $118M | |
| PP&E (Net) | $24M | $31M | $36M | $42M | $33M | $25M | $30M | $34M | $38M | $15M | $9M | $7M | |
| PP&E (Gross) | $117M | $112M | $111M | $107M | $89M | $75M | $74M | $71M | $70M | $52M | $42M | $37M | |
| Accum. Depreciation | $92M | $82M | $75M | $65M | $56M | $50M | $44M | $37M | $32M | $37M | $34M | $30M | |
| Goodwill | $318M | $318M | $462M | $410M | $410M | · | · | · | · | · | · | · | |
| Intangibles | $15M | $390M | $457M | $410M | $411M | · | · | · | · | · | · | · | |
| Other Non-current Assets | $9M | $9M | $13M | $11M | $1M | $43.0K | $42.0K | $43.0K | $45.0K | $10M | $8M | $29.0K | |
| Total Assets | $784M | $1.26B | $1.75B | $1.77B | $2.01B | $414M | $148M | $170M | $144M | $138M | $131M | $124M | |
| Accounts Payable | $21M | $17M | $15M | $12M | $11M | $4M | $8M | $7M | $9M | $8M | $5M | $6M | |
| Accrued Liabilities | $34M | $23M | $46M | $33M | $36M | $17M | $13M | $13M | $13M | $17M | $16M | $11M | |
| Short-term Debt | · | $0 | $490.0K | $2M | $2M | · | $16M | · | · | · | · | · | |
| Current Liabilities | $73M | $66M | $95M | $263M | $72M | $39M | $49M | $27M | $29M | $34M | $38M | $31M | |
| Capital Leases | $57M | $15M | $32M | $41M | $50M | $38M | $42M | · | · | · | · | $2M | |
| Other Non-current Liabilities | $0 | $546.0K | $751.0K | $1M | $3M | $752.0K | · | · | · | $2M | $1M | $2M | |
| Total Liabilities | $779M | $754M | $1.04B | $1.20B | $1.22B | $78M | $93M | $56M | $58M | $53M | $58M | $69M | |
| Long-term Debt | · | · | · | $897M | $896M | · | $16M | $15M | $14M | $16M | · | $14M | |
| Total Debt | · | $0 | $490.0K | $2M | $2M | · | $16M | · | · | · | · | · | |
| Common Stock | $302.0K | $294.0K | $268.0K | $227.0K | $221.0K | $192.0K | $153.0K | $150.0K | $116.0K | $93.0K | $80.0K | $74.0K | |
| Paid-in Capital | $2.70B | $2.65B | $2.54B | $2.10B | $2.01B | $1.37B | $1.12B | $1.10B | $966M | $872M | $787M | $736M | |
| Retained Earnings | $-2.70B | $-2.15B | $-1.84B | $-1.53B | $-1.22B | $-1.04B | $-1.07B | $-982M | $-880M | $-788M | $-713M | $-681M | |
| AOCI | $457.0K | $422.0K | $219.0K | $-5M | $-1M | $85.0K | $5.0K | $-36.0K | $-32.0K | $5.0K | $-7.0K | $9.0K | |
| Stockholders' Equity | $5M | $507M | $701M | $563M | $791M | $335M | $55M | $114M | $86M | $85M | $74M | $55M | |
| Liabilities + Equity | $784M | $1.26B | $1.75B | $1.77B | $2.01B | $414M | $148M | $170M | $144M | $138M | $131M | $124M | |
| Shares Outstanding | 301,956,000 | 294,418,000 | 267,744,000 | 226,505,000 | 220,978,000 | 192,294,000 | 153,119,000 | 150,244,000 | 116,277,000 | 92,677,000 | 79,983,000 | 73,927,000 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $7M | $8M | $4M | $4M | $4M | |
| Stock-based Comp | $42M | $71M | $72M | $79M | $73M | $18M | $16M | $23M | $20M | $20M | $14M | $10M | |
| Deferred Tax | $-546.0K | $-205.0K | $-11M | $0 | $-94M | · | · | · | · | · | · | · | |
| Amort. of Intangibles | $369M | $27M | $8M | $913.0K | $0 | $0 | $0 | · | · | · | · | · | |
| Restructuring | · | $13M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | · | · | $6M | $-4M | $-17M | $-34M | $528.0K | |
| Operating Cash Flow | $-111M | $-206M | $-259M | $-263M | $-111M | $20M | $-78M | $-66M | $-68M | $-68M | $-48M | $-51M | |
| CapEx | $3M | $6M | $9M | $17M | $6M | $1M | $3M | $2M | $10M | $8M | $3M | $2M | |
| Investing Cash Flow | $115M | $124M | $5M | $116M | $-679M | $-219M | $62M | $-38M | $-2M | $-15M | · | · | |
| Stock Issued | $0 | $0 | $189M | $0 | $32M | $46M | $9M | $10M | $9M | $8M | $7M | $4M | |
| Net Stock Activity | $0 | $0 | $15M | $11M | $32M | $46M | $9M | $10M | $9M | $8M | $7M | $4M | |
| Financing Cash Flow | $3M | $-43M | $109M | $10M | $1.17B | $252M | $27M | $107M | $69M | $66M | · | · | |
| Net Change in Cash | $8M | $-125M | $-146M | $-138M | $380M | · | · | · | $-258.0K | $-17M | $-3M | $10M | |
| Taxes Paid | $481.0K | $256.0K | $140.0K | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-114M | $-212M | $-268M | $-280M | $-117M | $18M | $-81M | $-68M | $-78M | $-76M | $-51M | $-53M | |
| Levered FCF | · | · | $-282M | · | $-125M | · | · | · | · | · | · | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 28.6% | 24.2% | 26.3% | 38.2% | 45.1% | 41.3% | 38.0% | 31.9% | 37.1% | 48.7% | 57.6% | 38.6% | |
| Operating Margin | -346.1% | -308.0% | -166.8% | -239.4% | -161.2% | -132.3% | -110.6% | -128.4% | -96.1% | -78.5% | -31.4% | -103.7% | |
| Net Margin | -341.5% | -201.2% | -153.0% | -244.9% | -138.8% | 37.3% | -92.6% | -130.4% | -98.6% | -82.0% | -34.2% | -109.2% | |
| Pretax Margin | -341.3% | -201.0% | -158.7% | -244.9% | -210.6% | · | · | · | · | · | · | · | |
| EBITDA Margin | -346.1% | -308.0% | -166.8% | -239.4% | -161.2% | -132.3% | -110.6% | -119.3% | -87.0% | -74.3% | -27.4% | -96.8% | |
| ROA | -53.4% | -20.6% | -17.5% | -16.7% | -15.0% | 10.5% | -52.9% | -65.2% | -65.4% | -55.3% | -24.8% | -50.7% | |
| ROE | -1634.9% | -64.6% | -41.9% | -52.8% | -22.2% | 12.7% | -158.8% | -83.4% | -108.0% | -94.0% | -49.3% | -106.6% | |
| ROIC | -10360.5% | -93.7% | -46.0% | · | -17.5% | · | · | · | · | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.1 | 7.5 | 7.8 | 3.2 | 15.4 | 9.2 | 1.6 | 4.9 | 3.5 | 3.2 | 2.9 | 3.7 | |
| Quick Ratio | 4.3 | 6.3 | 7.0 | 3.0 | 14.9 | 8.7 | 1.3 | 4.1 | 2.7 | 2.5 | 2.3 | 3.3 | |
| Debt / Equity | · | 0.0 | 0.0 | 0.0 | 0.0 | · | 0.3 | · | · | · | · | · | |
| Interest Coverage | · | · | -23.3 | -20.9 | -16.8 | -391.0 | -38.5 | -41.7 | -30.7 | -22.0 | -10.0 | -22.2 |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.3 | 0.6 | 0.5 | 0.7 | 0.7 | 0.7 | 0.5 | |
| Inventory Turnover | 2.1 | 2.0 | 2.8 | 2.1 | 3.7 | 3.4 | 3.6 | 2.6 | 3.0 | 3.5 | 3.5 | 3.5 | |
| Receivables Turnover | 5.1 | 4.8 | 7.2 | 6.0 | 6.4 | 4.9 | 7.6 | 7.1 | 7.5 | 10.9 | 21.4 | 19.7 |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.02 | $1.72 | $2.62 | $2.49 | $3.58 | $1.74 | $0.36 | $0.76 | $0.74 | $0.91 | $0.92 | $0.74 | |
| Revenue / Share | $0.53 | $0.53 | $0.79 | $0.57 | $0.64 | $0.45 | · | · | · | · | · | · | |
| Cash Flow / Share | $-0.37 | $-0.71 | $-1.02 | $-1.17 | $-0.54 | $0.11 | · | · | · | · | · | · | |
| Cash / Share | $0.21 | $0.19 | $0.67 | $1.44 | $2.08 | $0.42 | $0.19 | $0.13 | $0.14 | $0.18 | $0.42 | $0.49 | |
| Dividend / Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| EPS (TTM) | $-1.82 | $-1.59 | $-1.21 | $-1.40 | $-0.89 | $0.17 | $-0.55 | $-0.76 | · | · | · | · |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 3.9% | -23.2% | 56.3% | -1.7% | 65.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 7.6% | 5.7% | 36.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.2% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $160M | $154M | $201M | $128M | $131M | $79M | $91M | $79M | $93M | $91M | $93M | $61M | |
| Net Income TTM | $-546M | $-310M | $-307M | $-314M | $-181M | $29M | $-84M | $-103M | $-92M | $-74M | $-32M | $-66M | |
| Market Cap | $565M | $539M | $2.63B | $1.85B | $4.52B | $4.99B | $787M | $1.11B | $307M | $352M | $1.05B | $580M | |
| Enterprise Value | · | $149M | $2.00B | $1.08B | $3.48B | · | $754M | · | · | · | · | · | |
| P/E | -1.0 | -1.2 | -8.1 | -5.8 | -23.0 | 152.6 | -9.3 | -9.7 | · | · | · | · | |
| P/S | 3.5 | 3.5 | 13.1 | 14.4 | 34.6 | 63.2 | 8.7 | 14.1 | 3.3 | 3.9 | 11.3 | 9.6 | |
| P/B | 105.6 | 1.1 | 3.7 | 3.3 | 5.7 | 14.9 | 14.3 | 9.7 | 3.6 | 4.2 | 14.3 | 10.5 | |
| P / Tangible Book | · | · | · | · | · | 14.9 | · | · | · | · | · | · | |
| P / Cash Flow | -5.1 | -2.6 | -10.1 | -7.0 | -40.7 | 255.8 | -10.0 | -16.7 | -4.5 | -5.2 | -21.9 | -11.3 | |
| P / FCF | -5.0 | -2.5 | -9.8 | -6.6 | -38.6 | 270.2 | -9.7 | -16.3 | -3.9 | -4.6 | -20.6 | -10.9 | |
| EV / EBITDA | · | -0.3 | -6.0 | -3.5 | -16.5 | · | -7.5 | · | · | · | · | · | |
| EV / FCF | · | -0.7 | -7.4 | -3.9 | -29.7 | · | -9.3 | · | · | · | · | · | |
| EV / Revenue | · | 1.0 | 10.0 | 8.4 | 26.7 | · | 8.3 | · | · | · | · | · | |
| Earnings Yield | -97.3% | -86.9% | -12.3% | -17.1% | -4.3% | 0.66% | -10.7% | -10.3% | · | · | · | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39M | $37M | $45M | $38M | $40M | $37M | $39M | $40M | $36M | $39M | $58M | $56M | $48M | $39M | $27M | $32M | |
| Cost of Revenue | $26M | $24M | $28M | $23M | $25M | $39M | $29M | $30M | $30M | $28M | $49M | $38M | $32M | $29M | $22M | $19M | |
| Gross Profit | $13M | $13M | $17M | $16M | $15M | $-1M | $10M | $10M | $6M | $11M | $10M | $18M | $16M | $10M | $5M | $14M | |
| R&D Expense | $23M | $20M | $23M | $23M | $23M | $29M | $27M | $26M | $38M | $43M | $45M | $48M | $46M | $49M | $43M | $47M | |
| SG&A Expense | $33M | $31M | $34M | $31M | $36M | $40M | $42M | $44M | $46M | $44M | $46M | $43M | $41M | $40M | $45M | $37M | |
| Operating Expenses | $57M | $21M | $58M | $55M | $60M | $428M | $163M | $74M | $182M | $93M | $97M | $100M | $89M | $101M | $92M | $88M | |
| Operating Income | $-45M | $-8M | $-41M | $-39M | $-45M | $-429M | $-153M | $-64M | $-176M | $-81M | $-88M | $-82M | $-73M | $-91M | $-87M | $-75M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $4M | · | $4M | $4M | $4M | · | $4M | |
| Other Non-op | $2M | $2M | $3M | $3M | $5M | $4M | $4M | $7M | $6M | $7M | $8M | $9M | $9M | $7M | $6M | $1M | |
| Pretax Income | $-45M | $-8M | $-40M | $-38M | $-42M | $-426M | $3M | $-61M | $-173M | $-78M | $-83M | $-78M | $-70M | $-88M | $-84M | $-77M | |
| Income Tax | $58.0K | $184.0K | $202.0K | $383.0K | $35.0K | $-302.0K | $316.0K | $0 | $0 | $0 | $-718.0K | $-11M | $0 | $0 | $0 | $0 | |
| Net Income | $-45M | $-8M | $-40M | $-38M | $-42M | $-426M | $2M | $-61M | $-173M | $-78M | $-82M | $-67M | $-70M | $-88M | $-84M | $-77M | |
| EPS (Basic) | $-0.14 | $-0.03 | $-0.11 | $-0.13 | $-0.14 | $-1.44 | $0.02 | $-0.22 | $-0.64 | $-0.29 | $-0.31 | $-0.26 | $-0.28 | $-0.36 | $-0.37 | $-0.34 | |
| EPS (Diluted) | $-0.14 | $-0.03 | $-0.11 | $-0.13 | $-0.14 | $-1.44 | $-0.44 | $-0.22 | $-0.64 | $-0.29 | $-0.31 | $-0.26 | $-0.28 | $-0.36 | $-0.37 | $-0.34 | |
| Shares (Basic) | 310,655,000 | 305,819,000 | · | 300,844,000 | 300,162,000 | 296,858,000 | · | 272,915,000 | 272,385,000 | 269,578,000 | · | 255,001,000 | 250,070,000 | 242,032,000 | · | 225,123,000 | |
| Shares (Diluted) | 310,655,000 | 305,819,000 | · | 300,844,000 | 300,162,000 | 296,858,000 | · | 272,915,000 | 272,385,000 | 269,578,000 | · | 255,001,000 | 250,070,000 | 242,032,000 | · | 225,123,000 | |
| EBITDA | $-45M | $-8M | · | $-39M | $-45M | $-429M | · | $-64M | $-176M | $-81M | · | $-82M | $-73M | $-91M | · | $-75M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $61M | $56M | $64M | $56M | $55M | $59M | $55M | $78M | $100M | $77M | $180M | $386M | $209M | $354M | $325M | $304M | |
| Short-term Investments | $176M | $220M | $216M | $242M | $260M | $285M | $335M | $393M | $410M | $485M | · | $382M | $621M | $521M | · | $530M | |
| Receivables | $31M | $29M | $35M | $31M | $32M | $32M | $28M | $29M | $32M | $30M | · | $30M | $24M | $30M | · | $23M | |
| Inventory | $61M | $51M | $49M | $53M | $54M | $54M | $59M | $66M | $69M | $67M | · | $68M | $68M | $62M | · | $43M | |
| Prepaid Expense | $10M | $13M | $11M | $12M | $12M | $15M | $19M | $17M | $17M | $17M | · | $15M | $14M | $14M | · | $13M | |
| Current Assets | $339M | $370M | $375M | $394M | $413M | $445M | $496M | $584M | $628M | $677M | · | $882M | $936M | $981M | · | $914M | |
| PP&E (Net) | $27M | $24M | $24M | $22M | $23M | $25M | $31M | $32M | $35M | $37M | · | $40M | $40M | $41M | · | $39M | |
| PP&E (Gross) | · | · | $117M | · | · | · | $112M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $92M | · | · | · | $82M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $318M | $318M | $318M | $318M | $318M | $318M | $318M | $369M | $369M | $462M | · | $464M | $410M | $410M | · | $410M | |
| Intangibles | $13M | $14M | $15M | $16M | $17M | $18M | $390M | $436M | $443M | $450M | · | $462M | $410M | $410M | · | $410M | |
| Other Non-current Assets | $13M | $14M | $9M | $9M | $9M | $9M | $9M | $10M | $10M | $10M | · | $13M | $13M | $13M | · | $1M | |
| Total Assets | $752M | $782M | $784M | $803M | $825M | $861M | $1.26B | $1.45B | $1.51B | $1.67B | · | $1.90B | $1.85B | $1.90B | · | $1.82B | |
| Accounts Payable | $19M | $14M | $21M | $16M | $15M | $14M | $17M | $12M | $17M | $21M | · | $16M | $17M | $17M | · | $13M | |
| Accrued Liabilities | $30M | $34M | $34M | $29M | $27M | $29M | $23M | $19M | $22M | $22M | · | $35M | $27M | $19M | · | $25M | |
| Current Liabilities | $69M | $65M | $73M | $63M | $60M | $67M | $66M | $60M | $78M | $73M | · | $184M | $271M | $266M | · | $82M | |
| Capital Leases | $60M | $59M | $57M | $54M | $52M | $50M | $15M | $17M | $20M | $29M | · | $34M | $37M | $39M | · | $43M | |
| Other Non-current Liabilities | $8M | $8M | $0 | $0 | $0 | $0 | $546.0K | $751.0K | $751.0K | $751.0K | · | $1M | $837.0K | $969.0K | · | $2M | |
| Total Liabilities | $785M | $780M | $779M | $767M | $764M | $769M | $754M | $997M | $1.02B | $1.02B | · | $1.13B | $1.21B | $1.20B | · | $1.19B | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | $897M | · | $897M | |
| Common Stock | $311.0K | $311.0K | $302.0K | $302.0K | $300.0K | $300.0K | $294.0K | $274.0K | $272.0K | $272.0K | · | $258.0K | $250.0K | $250.0K | · | $226.0K | |
| Paid-in Capital | $2.72B | $2.71B | $2.70B | $2.69B | $2.68B | $2.67B | $2.65B | $2.60B | $2.58B | $2.57B | · | $2.52B | $2.33B | $2.31B | · | $2.08B | |
| Retained Earnings | $-2.75B | $-2.70B | $-2.70B | $-2.65B | $-2.62B | $-2.58B | $-2.15B | $-2.15B | $-2.09B | $-1.92B | · | $-1.76B | $-1.69B | $-1.62B | · | $-1.45B | |
| AOCI | $-503.0K | $-147.0K | $457.0K | $415.0K | $267.0K | $381.0K | $422.0K | $2M | $-523.0K | $-306.0K | · | $-2M | $-3M | $-2M | · | $-6M | |
| Stockholders' Equity | $-33M | $2M | $5M | $36M | $61M | $92M | $507M | $453M | $493M | $649M | $701M | $764M | $642M | $692M | $563M | $627M | |
| Liabilities + Equity | $752M | $782M | $784M | $803M | $825M | $861M | $1.26B | $1.45B | $1.51B | $1.67B | · | $1.90B | $1.85B | $1.90B | · | $1.82B | |
| Shares Outstanding | 310,810,000 | 310,487,000 | 301,956,000 | 301,853,000 | 300,350,000 | 300,041,000 | 294,418,000 | 273,812,000 | 272,491,000 | 272,280,000 | 267,744,000 | 258,374,000 | 250,473,000 | 249,803,000 | 226,505,000 | 225,916,000 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $9M | $4M | $10M | $11M | $12M | $9M | $16M | $18M | $17M | $20M | $17M | $20M | $18M | $18M | $18M | $19M | |
| Amort. of Intangibles | · | $1M | $1M | $1M | $1M | $366M | $7M | $7M | $7M | $7M | $7M | $942.0K | $232.0K | $234.0K | $228.0K | $229.0K | |
| Restructuring | · | · | · | · | · | · | · | · | $11M | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-36M | $-45M | $-19M | $-19M | $-29M | $-44M | $-31M | $-45M | $-54M | $-76M | $-58M | $-65M | $-42M | $-95M | $-61M | $-63M | |
| CapEx | $2M | $3M | $861.0K | $-86.0K | $550.0K | $1M | $2M | $-787.0K | $1M | $4M | $2M | $830.0K | $2M | $4M | $5M | $4M | |
| Investing Cash Flow | $40M | $36M | $26M | $19M | $25M | $45M | $58M | $23M | $77M | $-34M | $-67M | $242M | $-99M | $-73M | $80M | $54M | |
| Stock Issued | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $189M | $0 | $-6M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $189M | · | · | |
| Financing Cash Flow | $255.0K | $1M | $0 | $1M | $0 | $2M | $-50M | $812.0K | $-152.0K | $7M | $-82M | $-781.0K | $-5M | $196M | $819.0K | $3M | |
| Net Change in Cash | $5M | $-7M | $7M | $2M | $-4M | $3M | $-23M | $-22M | $22M | $-103M | $-206M | $176M | $-145M | $29M | $21M | $-6M | |
| Free Cash Flow | · | $-48M | · | · | · | $-45M | · | · | · | $-80M | · | · | · | $-98M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-83M | · | · | · | $-102M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 32.4% | 34.5% | · | 41.4% | 36.9% | -3.7% | · | 25.0% | 16.5% | 29.1% | · | 32.1% | 32.7% | 25.1% | · | 41.9% | |
| Operating Margin | -114.4% | -22.5% | · | -101.1% | -112.8% | -1154.5% | · | -160.3% | -488.3% | -209.6% | · | -148.1% | -153.8% | -234.6% | · | -230.9% | |
| Net Margin | -114.7% | -22.3% | · | -98.9% | -105.4% | -1146.8% | · | -151.9% | -481.3% | -201.4% | · | -120.1% | -146.8% | -226.3% | · | -238.2% | |
| Pretax Margin | -114.5% | -21.8% | · | -97.9% | -105.4% | -1147.6% | · | -151.9% | -481.3% | -201.4% | · | -139.3% | -146.8% | -226.3% | · | -238.2% | |
| EBITDA Margin | -114.4% | -22.5% | · | -101.1% | -112.8% | -1154.5% | · | -160.3% | -488.3% | -209.6% | · | -148.1% | -153.8% | -234.6% | · | -230.9% | |
| ROA | -5.7% | -1.0% | · | -3.4% | -3.6% | -33.7% | · | -3.6% | -10.3% | -4.4% | · | -3.6% | -3.8% | -4.6% | · | -4.0% | |
| ROE | -316.5% | -17.6% | · | -15.5% | -15.1% | -115.1% | · | -10.0% | -30.6% | -11.7% | · | -9.6% | -10.5% | -12.3% | · | -10.5% | |
| ROIC | 134.5% | -361.2% | · | -108.8% | -73.0% | -467.7% | · | -14.1% | -35.7% | -12.5% | · | -9.3% | -11.4% | -13.2% | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.9 | 5.7 | · | 6.2 | 6.9 | 6.7 | · | 9.7 | 8.0 | 9.3 | · | 4.8 | 3.4 | 3.7 | · | 11.2 | |
| Quick Ratio | 3.9 | 4.7 | · | 5.2 | 5.8 | 5.6 | · | 8.3 | 6.9 | 8.1 | · | 4.3 | 3.1 | 3.4 | · | 10.5 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -22.8 | · | -23.0 | -20.6 | -25.1 | · | -20.4 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.5 | 0.5 | · | 0.4 | 0.4 | 0.6 | · | 0.4 | 0.4 | 0.4 | · | 0.7 | 0.6 | 0.6 | · | 0.6 | |
| Receivables Turnover | 1.2 | 1.2 | · | 1.3 | 1.2 | 1.2 | · | 1.3 | 1.3 | 1.3 | · | 2.1 | 1.9 | 1.4 | · | 1.4 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.11 | $0.01 | · | $0.12 | $0.20 | $0.31 | · | $1.65 | $1.81 | $2.38 | · | $2.96 | $2.56 | $2.77 | · | $2.77 | |
| Revenue / Share | $0.13 | $0.12 | · | $0.13 | $0.13 | $0.13 | · | $0.15 | $0.13 | $0.14 | · | $0.22 | $0.19 | $0.16 | · | $0.14 | |
| Cash Flow / Share | · | $-0.15 | · | · | · | $-0.15 | · | · | · | $-0.28 | · | · | · | $-0.39 | · | · | |
| Cash / Share | $0.20 | $0.18 | · | $0.19 | $0.18 | $0.20 | · | $0.28 | $0.37 | $0.28 | · | $1.49 | $0.84 | $1.42 | · | $1.35 | |
| EPS (TTM) | $-0.41 | $-0.41 | · | $-2.15 | $-2.24 | $-2.74 | · | $-1.46 | $-1.50 | $-1.14 | · | $-1.27 | $-1.35 | $-1.39 | · | $-1.34 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $159M | $160M | · | $155M | $156M | $152M | · | $173M | $189M | $200M | · | $170M | $146M | $134M | · | $137M | |
| Net Income TTM | $-131M | $-129M | · | $-504M | $-526M | $-658M | · | $-394M | $-400M | $-297M | · | $-309M | $-319M | $-321M | · | $-299M | |
| Market Cap | $522M | $410M | · | $386M | $372M | $354M | · | $465M | $373M | $1.02B | · | $2.16B | $3.33B | $2.89B | · | $1.31B | |
| P/E | -4.1 | -3.2 | · | -0.6 | -0.6 | -0.4 | · | -1.2 | -0.9 | -3.3 | · | -6.6 | -9.9 | -8.3 | · | -4.3 | |
| P/S | 3.3 | 2.6 | · | 2.5 | 2.4 | 2.3 | · | 2.7 | 2.0 | 5.1 | · | 12.7 | 22.8 | 21.6 | · | 9.6 | |
| P/B | -15.7 | 173.2 | · | 10.7 | 6.1 | 3.9 | · | 1.0 | 0.8 | 1.6 | · | 2.8 | 5.2 | 4.2 | · | 2.1 | |
| P / Cash Flow | · | -9.2 | · | · | · | -8.0 | · | · | · | -13.5 | · | · | · | -30.5 | · | · | |
| Earnings Yield | -24.4% | -31.1% | · | -168.0% | -180.7% | -232.2% | · | -85.9% | -109.5% | -30.4% | · | -15.2% | -10.2% | -12.0% | · | -23.1% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $160M | $154M | $201M | $128M | $131M |
| Bruttogewinnmarge % | 28.6% | 24.2% | 26.3% | 38.2% | 45.1% |
| Betriebsgewinnmarge % | -346.1% | -308.0% | -166.8% | -239.4% | -161.2% |
| Nettoergebnis | $-546M | $-310M | $-307M | $-314M | $-181M |
| Verwässerte EPS | $-1.82 | $-1.59 | $-1.21 | $-1.40 | $-0.89 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | · | 0.0 | 0.0 | 0.0 | 0.0 |
| Liquiditätsgrad | 5.1 | 7.5 | 7.8 | 3.2 | 15.4 |
| Quick Ratio | 4.3 | 6.3 | 7.0 | 3.0 | 14.9 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-114M | $-212M | $-268M | $-280M | $-117M |
Institutionelle Eigentümer (13F) 244 Einreicher · $360.0M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
244
Gehaltener Wert
$360.0M
Neue Positionen
24
Geschlossene Positionen
28
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 24 (-30 vs. Vorquartal) | 28 (-2 vs. Vorquartal) | 72 (+14 vs. Vorquartal) | 80 (+4 vs. Vorquartal) | +4.3M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| BlackRock, Inc. | $54.330.444 | 32.339.550 | 15,09% | Aktien |
| ARK Investment Management LLC | $50.032.778 | 29.781.416 | 13,90% | Aktien |
| SOFTBANK GROUP CORP. | $34.358.638 | 20.451.570 | 9,54% | Aktien |
| VANGUARD GROUP INC | $31.859.776 | 17.037.314 | 8,85% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $22.508.529 | 13.397.934 | 6,25% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $12.782.429 | 7.606.518 | 3,55% | Aktien |
| Sumitomo Mitsui Trust Group, Inc. | $10.096.321 | 6.009.715 | 2,80% | Aktien |
| Amova Asset Management Americas, Inc. | $10.036.224 | 6.009.715 | 2,79% | Aktien |
| STATE STREET CORP | $10.014.774 | 5.961.175 | 2,78% | Aktien |
| Point72 Asset Management, L.P. | $8.042.664 | 4.787.300 | 2,23% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $7.127.566 | 4.242.599 | 1,98% | Aktien |
| D. E. Shaw & Co., Inc. | $7.069.686 | 4.208.146 | 1,96% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $6.656.903 | 3.962.442 | 1,85% | Aktien |
| Point72 (DIFC) Ltd | $5.465.775 | 4.270.137 | 1,52% | Aktien |
| GOLDMAN SACHS GROUP INC | $5.426.210 | 3.229.887 | 1,51% | Aktien |
| CITADEL ADVISORS LLC | $4.781.117 | 2.845.903 | 1,33% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $4.488.819 | 2.671.916 | 1,25% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $4.455.861 | 2.652.298 | 1,24% | Aktien |
| NORTHERN TRUST CORP | $3.952.681 | 2.352.786 | 1,10% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $3.675.213 | 2.187.627 | 1,02% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $3.577.162 | 2.129.263 | 0,99% | Aktien |
| Longaeva Partners L.P. | $3.558.628 | 2.118.231 | 0,99% | Aktien |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | $2.846.837 | 1.694.546 | 0,79% | Aktien |
| Birchview Capital, LP | $2.268.000 | 1.350.000 | 0,63% | Aktien |
| BANK OF AMERICA CORP /DE/ | $2.264.860 | 1.348.131 | 0,63% | Aktien |
| Invesco Ltd. | $2.179.114 | 1.297.091 | 0,61% | Aktien |
| AQR CAPITAL MANAGEMENT LLC | $2.178.430 | 1.296.684 | 0,61% | Aktien |
| Nuveen, LLC | $1.718.830 | 1.023.113 | 0,48% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $1.623.216 | 966.200 | 0,45% | Aktien |
| BOURNE LENT ASSET MANAGEMENT INC | $1.584.332 | 943.055 | 0,44% | Aktien |
| TWO SIGMA ADVISERS, LP | $1.547.425 | 827.500 | 0,43% | Aktien |
| HHLR ADVISORS, LTD. | $1.543.739 | 918.892 | 0,43% | Aktien |
| UBS Group AG | $1.500.475 | 893.140 | 0,42% | Aktien |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $1.358.616 | 808.700 | 0,38% | Aktien |
| Bank of New York Mellon Corp | $1.289.512 | 767.567 | 0,36% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $1.277.135 | 759.783 | 0,35% | Aktien |
| Casdin Capital, LLC | $1.215.929 | 723.767 | 0,34% | Aktien |
| TUDOR INVESTMENT CORP ET AL | $1.150.308 | 684.707 | 0,32% | Aktien |
| XTX Topco Ltd | $1.073.322 | 638.882 | 0,30% | Aktien |
| Numerai GP LLC | $1.044.068 | 621.469 | 0,29% | Aktien |
| CARRET ASSET MANAGEMENT, LLC | $1.008.235 | 600.140 | 0,28% | Aktien |
| Man Group plc | $1.003.521 | 597.334 | 0,28% | Aktien |
| Russell Investments Group, Ltd. | $1.002.694 | 596.843 | 0,28% | Aktien |
| Balyasny Asset Management L.P. | $948.090 | 564.339 | 0,26% | Aktien |
| PEAK6 LLC | $933.327 | 555.552 | 0,26% | Aktien |
| Vestmark Advisory Solutions, Inc. | $803.384 | 478.205 | 0,22% | Aktien |
| MORGAN STANLEY | $802.664 | 477.776 | 0,22% | Aktien |
| ArrowMark Colorado Holdings LLC | $786.882 | 468.382 | 0,22% | Aktien |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $741.954 | 441.639 | 0,21% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $673.008 | 400.600 | 0,19% | Verkaufsoption |
Aktivisten & 5%+-Eigentümer 1 Beteiligung
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Magnetar Financial LLC, Magnetar Capital Partners LP, Supernova Management LLC, Alec N. Litowitz ×3 Einreichungen | 29. August 2019 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 30 Insider · 6 Führungskräfte · 11 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Mark Van Oene | President & CEO | 17. August 2026 S | 2.705.853 | 0 | 4 | $-335.122 |
| Susan K Barnes | EVP, CFO and PAO | 19. Februar 2020 S | 874.812 | 0 | 0 | $0 |
| James Michael Phillips | SVP, Research & Development | 24. März 2020 S | 249.220 | 0 | 0 | $0 |
| Kevin P Corcoran | SVP, Market Development | 24. November 2017 M | 158.174 | 0 | 0 | $0 |
| Michael Glynn | Chief Commercial Officer | 15. Februar 2012 A | · | 0 | 0 | $0 |
| Stephen W Turner | VP & Chief Technology Officer | 11. Juli 2011 J | 1.093.063 | 0 | 0 | $0 |
| Christopher Gibson | Direktor | 3. Juni 2026 A | 111.386 | 0 | 0 | $0 |
| Hannah Valantine | Direktor | 3. Juni 2026 A | 22.821 | 0 | 0 | $0 |
| William W. Ericson | Direktor | 3. Juni 2026 A | 41.616 | 0 | 0 | $0 |
| Christopher M Smith | Direktor | 3. Juni 2026 A | 54.099 | 0 | 0 | $0 |
| Marshall Mohr | Direktor | 3. Juni 2026 A | 132.821 | 0 | 0 | $0 |
| Randall S Livingston | Direktor | 3. Juni 2026 A | 22.821 | 0 | 0 | $0 |
| Kathy Ordonez | Direktor | 3. Juni 2026 A | 403.037 | 0 | 0 | $0 |
| John F Milligan | Direktor | 3. Juni 2026 A | 132.821 | 0 | 0 | $0 |
| David B. Singer | Direktor | 13. Juni 2012 A | · | 0 | 0 | $0 |
| Susan E Siegel | Direktor | 13. Juni 2012 A | 65.000 | 0 | 0 | $0 |
| Hugh C Martin | Direktor | 3. Februar 2012 M | 342.458 | 0 | 0 | $0 |
| James R Gibson II | · | 1. April 2026 S | 1.245.663 | 0 | 1 | $-120.813 |
| Michele Farmer | · | 3. März 2026 S | 305.948 | 0 | 3 | $-84.510 |
| Christian O Henry | · | 3. März 2026 S | 3.581.813 | 0 | 3 | $-772.728 |
| Lucy Shapiro | · | 4. Juni 2025 A | 22.821 | 0 | 0 | $0 |
| Susan G. Kim | · | 30. September 2024 S | 695.654 | 0 | 0 | $0 |
| Jeff Eidel | · | 19. August 2024 S | 869.730 | 0 | 0 | $0 |
| David W Meline | · | 18. Juni 2024 A | 57.116 | 0 | 0 | $0 |
| David Botstein | · | 24. Mai 2023 A | 0 | 0 | 0 | $0 |
| Peter Fromen | · | 2. März 2022 A | 190.280 | 0 | 0 | $0 |
| Michael Hunkapiller | · | 26. Februar 2021 M | 848.405 | 0 | 0 | $0 |
| Eric Schaefer | · | 22. Februar 2021 S | 88.474 | 0 | 0 | $0 |
| BYERS BROOK H | · | 17. Mai 2016 A | 110.504 | 0 | 0 | $0 |
| Brian B Dow | · | 2. März 2015 P | 18.119 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 21 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,97% | 88.548 SH | 2. Oktober 2026 | Täglich |
| ARKG · ARK ETF Trust | 0,96% | 10.630.263 NS | 31. Juli 2026 | N-PORT |
| IDNA · iShares Trust | 0,35% | 711.655 SH | 11. September 2026 | Täglich |
| ARKK · ARK ETF Trust | 0,32% | 12.810.378 NS | 31. Juli 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,09% | 981.246 SH | 2. Oktober 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,05% | 21.993 SH | 2. Oktober 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,03% | 280.941 SH | 19. August 2026 | Täglich |
| IBB · iShares Trust | 0,03% | 2.192.352 SH | 11. September 2026 | Täglich |
| IWO · iShares Trust | 0,02% | 2.473.318 SH | 11. September 2026 | Täglich |
| RSSL · Global X Funds | 0,01% | 134.834 NS | 31. Juli 2026 | N-PORT |
| IWM · iShares Trust | 0,01% | 7.217.251 SH | 11. September 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 3.579.782 SH | 19. August 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 1.624.029 SH | 19. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,01% | 727.094 SH | 19. August 2026 | Täglich |
| ITOT · iShares Trust | 0,00% | 431.328 SH | 11. September 2026 | Täglich |
| IWV · iShares Trust | 0,00% | 69.680 SH | 9. September 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 9.535.565 SH | 19. August 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,00% | 17.047 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 22.805 SH | 19. August 2026 | Täglich |
| DFAC · Dimensional ETF Trust | 0,00% | 8.144 NS | 31. Juli 2026 | N-PORT |
| IWN · iShares Trust | · | 207.024 SH | 11. September 2026 | Täglich |
PACB Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 14 Analysten
KAUF
Median-Ziel
$2.00
-21,3%
4 28,6%
Starker Kauf
5 35,7%
Kauf
4 28,6%
Halten
1 7,1%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
7 Analysten · 2026-10-02Mittelwert-Ziel $2.16 -15,1%
Jetzt
Aktueller Preis $2.54
Tief$1.25
Mittelwert$2.16
Hoch$3.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| PACB | $565M | -1.0 | 3.9% | -341.5% | -1634.9% | 28.6% |
| BLFS | · | -241.8 | 28.9% | · | · | · |
| PSNL | $816M | -8.7 | -17.7% | -116.7% | -36.0% | · |
| AZTA | $1.32B | -23.5 | 3.5% | -9.4% | -3.3% | 45.5% |
| CYRX | $479M | 6.9 | 12.4% | 44.4% | 15.3% | 47.1% |
| DNA | $484M | -1.5 | -25.1% | -183.8% | -55.8% | · |
| CTKB | $649M | 505.0 | 0.52% | -33.0% | -18.5% | 51.8% |
| MLAB | $489M | 73.1 | 3.4% | 2.7% | 3.7% | 63.5% |
| OABI | · | · | · | · | · | · |
| TKNO | $204M | -11.9 | 7.3% | -42.6% | -23.8% | 33.2% |
| QSI | · | · | · | · | · | · |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 6, 2026